-
公开(公告)号：US20230346903A1
公开(公告)日：2023-11-02
申请号：US18060779
申请日：2022-12-01
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
CPC classification number: A61K39/092 , C07K16/1275 , C07K16/44 , A61K39/39 , A61K39/40 , A61K47/10 , A61K47/26 , A61K2039/505
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20210145957A1
公开(公告)日：2021-05-20
申请号：US17161119
申请日：2021-01-28
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B. streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
Patent Agency Ranking
公开(公告)号：US10946086B2
公开(公告)日：2021-03-16
申请号：US16245378
申请日：2019-01-11
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G. K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20190142922A1
公开(公告)日：2019-05-16
申请号：US16245378
申请日：2019-01-11
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
5.发明申请GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF 审中-公开B组STR多糖聚糖 - 蛋白质结合体，生产结合物的方法，包含结合物的免疫组合物及其用途公开(公告)号：US20160324950A1
公开(公告)日：2016-11-10
申请号：US15144884
申请日：2016-05-03
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
CPC classification number: A61K39/092 , A61K39/39 , A61K39/40 , A61K47/10 , A61K47/26 , A61K2039/505 , A61K2039/55 , A61K2039/55505 , A61K2039/55566 , A61K2039/55577 , A61K2039/6037 , A61K2039/70 , C07K16/1275 , C07K16/44 , Y02A50/484
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
Abstract translation: 本发明涉及免疫原性多糖 - 蛋白质缀合物，其包含通常称为B族链球菌（GBS）的无乳链球菌的荚膜多糖（CP）和载体蛋白，其中CP选自血清型Ia，Ib ，II，III，IV，V，VI，VII，VIII和IX，并且其中CP具有大于约60％的唾液酸水平。 本发明还涉及制备缀合物和包含缀合物的免疫原性组合物的方法。 本发明还涉及包含多糖 - 蛋白质缀合物的免疫原性组合物，其中缀合物包含来自GBS血清型IV的CP和至少一种另外的血清型。 本发明还涉及使用本文公开的组合物在受试者中诱导免疫应答的方法，所述方法用于针对GBS和/或用于减少或预防受试者的侵袭性GBS疾病。 所得抗体可用于通过被动免疫治疗来治疗或预防GBS感染。
-
公开(公告)号：US20240000912A1
公开(公告)日：2024-01-04
申请号：US18034239
申请日：2021-11-01
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Seema Shridhar Gangolli , Kathrin Ute Jansen , Avvari Krishna Prasad , Michael William Pride , Ingrid Lea Scully , Wendy Jo Watson
CPC classification number: A61K39/092 , A61P31/04 , A61K2039/70
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 15, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
-
公开(公告)号：US10226525B2
公开(公告)日：2019-03-12
申请号：US15144884
申请日：2016-05-03
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G. K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
-
-
-
-
-
Search Results
7
records
(took 0.019 seconds)
